Pfizer's Revenue
- Pfizer's annual revenue was $58.50B in fiscal year 2023. The annual revenue decreased -$41.83B from $100.33B (in 2022) to $58.50B (in 2023), representing a -41.70% year-over-year decline.
- Pfizer's quarterly revenue was $17.70B in the quarter ending Sep 2024. The quarterly revenue increased $4.47B from $13.23B (in Q3: June 2023) to $17.70B (in Q3: June 2024), representing a 33.78% year-over-year growth.
- The highest annual revenue for Pfizer was $100.33B in fiscal year 2022.
- The lowest annual revenue was $41.91B in fiscal year 2020.
- The average revenue was $60.18B.
- Revenue is the amount of money generated by a business from sales of its goods or services. Refer to our glossary for more details, examples, and formulas.
Over the past 10 years (2015 - 2024):
Learn more about Pfizer's Revenue by Segment and Revenue by Region.
Check out competitors to Pfizer in a side-by-side comparison.
Explore additional financial metrics for Pfizer.
Definition of Revenue :
2014 | 49605000000.00 |
---|---|
2015 | 48851000000.00 |
2016 | 52824000000.00 |
2017 | 52546000000.00 |
2018 | 53647000000.00 |
2019 | 51750000000.00 |
2020 | 41908000000.00 |
2021 | 81288000000.00 |
2022 | 100330000000.00 |
2023 | 58496000000.00 |
Mar 2015 | 10864000000.00 |
---|---|
Jun 2015 | 11853000000.00 |
Sep 2015 | 12087000000.00 |
Dec 2015 | 14047000000.00 |
Apr 2016 | 13005000000.00 |
Jul 2016 | 13147000000.00 |
Oct 2016 | 13045000000.00 |
Dec 2016 | 13627000000.00 |
Apr 2017 | 12779000000.00 |
Jul 2017 | 12896000000.00 |
Oct 2017 | 13168000000.00 |
Dec 2017 | 13703000000.00 |
Apr 2018 | 12906000000.00 |
Jul 2018 | 13466000000.00 |
Sep 2018 | 13298000000.00 |
Dec 2018 | 13976000000.00 |
Mar 2019 | 13118000000.00 |
Jun 2019 | 13264000000.00 |
Sep 2019 | 12680000000.00 |
Dec 2019 | 12688000000.00 |
Mar 2020 | 12028000000.00 |
Jun 2020 | 11801000000.00 |
Sep 2020 | 12131000000.00 |
Dec 2020 | 11684000000.00 |
Apr 2021 | 14582000000.00 |
Jul 2021 | 18977000000.00 |
Oct 2021 | 24094000000.00 |
Dec 2021 | 23838000000.00 |
Apr 2022 | 25661000000.00 |
Jul 2022 | 27742000000.00 |
Oct 2022 | 22638000000.00 |
Dec 2022 | 24290000000.00 |
Apr 2023 | 18282000000.00 |
Jul 2023 | 12734000000.00 |
Oct 2023 | 13232000000.00 |
Dec 2023 | 14249000000.00 |
Mar 2024 | 14879000000.00 |
Jun 2024 | 13283000000.00 |
Sep 2024 | 17702000000.00 |
2023
Pfizer's annual revenue was $58.50B in fiscal year 2023.
Pfizer's quarterly revenue was $18.28B(Q1: Apr 2023), $12.73B(Q2: Jul 2023), $13.23B(Q3: Oct 2023), $14.25B(Q4: Dec 2023) in fiscal year 2023.
2022
Pfizer's annual revenue was $100.33B in fiscal year 2023.
Pfizer's quarterly revenue was $25.66B(Q1: Apr 2022), $27.74B(Q2: Jul 2022), $22.64B(Q3: Oct 2022), $24.29B(Q4: Dec 2022) in fiscal year 2022.
2021
Pfizer's annual revenue was $81.29B in fiscal year 2023.
Pfizer's quarterly revenue was $14.58B(Q1: Apr 2021), $18.98B(Q2: Jul 2021), $24.09B(Q3: Oct 2021), $23.84B(Q4: Dec 2021) in fiscal year 2021.
2020
Pfizer's annual revenue was $41.91B in fiscal year 2023.
Pfizer's quarterly revenue was $12.03B(Q1: Mar 2020), $11.80B(Q2: Jun 2020), $12.13B(Q3: Sep 2020), $11.68B(Q4: Dec 2020) in fiscal year 2020.
2019
Pfizer's annual revenue was $51.75B in fiscal year 2023.
Pfizer's quarterly revenue was $13.12B(Q1: Mar 2019), $13.26B(Q2: Jun 2019), $12.68B(Q3: Sep 2019), $12.69B(Q4: Dec 2019) in fiscal year 2019.
2018
Pfizer's annual revenue was $53.65B in fiscal year 2023.
Pfizer's quarterly revenue was $12.91B(Q1: Apr 2018), $13.47B(Q2: Jul 2018), $13.30B(Q3: Sep 2018), $13.98B(Q4: Dec 2018) in fiscal year 2018.
2017
Pfizer's annual revenue was $52.55B in fiscal year 2023.
Pfizer's quarterly revenue was $12.78B(Q1: Apr 2017), $12.90B(Q2: Jul 2017), $13.17B(Q3: Oct 2017), $13.70B(Q4: Dec 2017) in fiscal year 2017.
2016
Pfizer's annual revenue was $52.82B in fiscal year 2023.
Pfizer's quarterly revenue was $13.01B(Q1: Apr 2016), $13.15B(Q2: Jul 2016), $13.05B(Q3: Oct 2016), $13.63B(Q4: Dec 2016) in fiscal year 2016.
2015
Pfizer's annual revenue was $48.85B in fiscal year 2023.
Pfizer's quarterly revenue was $10.86B(Q1: Mar 2015), $11.85B(Q2: Jun 2015), $12.09B(Q3: Sep 2015), $14.05B(Q4: Dec 2015) in fiscal year 2015.
2014 | 0 |
---|---|
2015 | -1.52 |
2016 | +8.13 |
2017 | -0.53 |
2018 | +2.10 |
2019 | -3.54 |
2020 | -19.02 |
2021 | +93.97 |
2022 | +23.43 |
2023 | -41.70 |
Q1: Mar 15 | -4.31 |
---|---|
Q2: Jun 15 | -7.20 |
Q3: Sep 15 | -2.22 |
Q4: Dec 15 | 7.08 |
Q1: Apr 16 | 19.71 |
Q2: Jul 16 | 10.92 |
Q3: Oct 16 | 7.93 |
Q4: Dec 16 | -2.99 |
Q1: Apr 17 | -1.74 |
Q2: Jul 17 | -1.91 |
Q3: Oct 17 | 0.94 |
Q4: Dec 17 | 0.56 |
Q1: Apr 18 | 0.99 |
Q2: Jul 18 | 4.42 |
Q3: Sep 18 | 0.99 |
Q4: Dec 18 | 1.99 |
Q1: Mar 19 | 1.64 |
Q2: Jun 19 | -1.50 |
Q3: Sep 19 | -4.65 |
Q4: Dec 19 | -9.22 |
Q1: Mar 20 | -8.31 |
Q2: Jun 20 | -11.03 |
Q3: Sep 20 | -4.33 |
Q4: Dec 20 | -7.91 |
Q1: Apr 21 | 21.23 |
Q2: Jul 21 | 60.81 |
Q3: Oct 21 | 98.62 |
Q4: Dec 21 | 104.02 |
Q1: Apr 22 | 75.98 |
Q2: Jul 22 | 46.19 |
Q3: Oct 22 | -6.04 |
Q4: Dec 22 | 1.90 |
Q1: Apr 23 | -28.76 |
Q2: Jul 23 | -54.10 |
Q3: Oct 23 | -41.55 |
Q4: Dec 23 | -41.34 |
Q1: Mar 24 | -18.61 |
Q2: Jun 24 | 4.31 |
Q3: Sep 24 | 33.78 |
2023
Pfizer’s annual revenue decreased -41.70% during fiscal year 2023 compared to 2022. It represents a decline of -$41.83B from $100.33B (in 2022) to $58.50B (in 2023).
2022
Pfizer’s annual revenue increased +23.43% during fiscal year 2022 compared to 2021. It represents a growth of $19.04B from $81.29B (in 2021) to $100.33B (in 2022).
2021
Pfizer’s annual revenue increased +93.97% during fiscal year 2021 compared to 2020. It represents a growth of $39.38B from $41.91B (in 2020) to $81.29B (in 2021).
2020
Pfizer’s annual revenue decreased -19.02% during fiscal year 2020 compared to 2019. It represents a decline of -$9.84B from $51.75B (in 2019) to $41.91B (in 2020).
2019
Pfizer’s annual revenue decreased -3.54% during fiscal year 2019 compared to 2018. It represents a decline of -$1.90B from $53.65B (in 2018) to $51.75B (in 2019).
2018
Pfizer’s annual revenue increased +2.10% during fiscal year 2018 compared to 2017. It represents a growth of $1.10B from $52.55B (in 2017) to $53.65B (in 2018).
2017
Pfizer’s annual revenue decreased -0.53% during fiscal year 2017 compared to 2016. It represents a decline of -$278.00M from $52.82B (in 2016) to $52.55B (in 2017).
2016
Pfizer’s annual revenue increased +8.13% during fiscal year 2016 compared to 2015. It represents a growth of $3.97B from $48.85B (in 2015) to $52.82B (in 2016).
2015
Pfizer’s annual revenue decreased -1.52% during fiscal year 2015 compared to 2014. It represents a decline of -$754.00M from $49.61B (in 2014) to $48.85B (in 2015).
Summary Table (Annual)
Period | Revenue | Year-over-Year Change |
---|---|---|
2023 | $58.50B | -41.70% |
2022 | $100.33B | +23.43% |
2021 | $81.29B | +93.97% |
2020 | $41.91B | -19.02% |
2019 | $51.75B | -3.54% |
2018 | $53.65B | +2.10% |
2017 | $52.55B | -0.53% |
2016 | $52.82B | +8.13% |
2015 | $48.85B | -1.52% |
Summary Table (Quarterly)
Period | Revenue | Year-over-Year Change |
---|---|---|
Q3: Sep 24 | $17.70B | 33.78% |
Q2: Jun 24 | $13.28B | 4.31% |
Q1: Mar 24 | $14.88B | -18.61% |
Q4: Dec 23 | $14.25B | -41.34% |
Q3: Oct 23 | $13.23B | -41.55% |
Q2: Jul 23 | $12.73B | -54.10% |
Q1: Apr 23 | $18.28B | -28.76% |
Q4: Dec 22 | $24.29B | 1.90% |
Q3: Oct 22 | $22.64B | -6.04% |
Q2: Jul 22 | $27.74B | 46.19% |
Q1: Apr 22 | $25.66B | 75.98% |
Q4: Dec 21 | $23.84B | 104.02% |
Q3: Oct 21 | $24.09B | 98.62% |
Q2: Jul 21 | $18.98B | 60.81% |
Q1: Apr 21 | $14.58B | 21.23% |
Q4: Dec 20 | $11.68B | -7.91% |
Q3: Sep 20 | $12.13B | -4.33% |
Q2: Jun 20 | $11.80B | -11.03% |
Q1: Mar 20 | $12.03B | -8.31% |
Q4: Dec 19 | $12.69B | -9.22% |
Q3: Sep 19 | $12.68B | -4.65% |
Q2: Jun 19 | $13.26B | -1.50% |
Q1: Mar 19 | $13.12B | 1.64% |
Q4: Dec 18 | $13.98B | 1.99% |
Q3: Sep 18 | $13.30B | 0.99% |
Q2: Jul 18 | $13.47B | 4.42% |
Q1: Apr 18 | $12.91B | 0.99% |
Q4: Dec 17 | $13.70B | 0.56% |
Q3: Oct 17 | $13.17B | 0.94% |
Q2: Jul 17 | $12.90B | -1.91% |
Q1: Apr 17 | $12.78B | -1.74% |
Q4: Dec 16 | $13.63B | -2.99% |
Q3: Oct 16 | $13.05B | 7.93% |
Q2: Jul 16 | $13.15B | 10.92% |
Q1: Apr 16 | $13.01B | 19.71% |
Q4: Dec 15 | $14.05B | 7.08% |
Q3: Sep 15 | $12.09B | -2.22% |
Q2: Jun 15 | $11.85B | -7.20% |
Q1: Mar 15 | $10.86B | -4.31% |